ALXN:NSD-Alexion Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 114.13

Change

-2.44 (-2.09)%

Market Cap

USD 25.55B

Volume

2.75M

Average Target Price

USD 142.14 (+24.54%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaboration with Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.91 (+1.46%)

USD69.69B 32.32 25.77
REGN Regeneron Pharmaceuticals, Inc

-4.15 (-0.73%)

USD63.99B 21.32 16.47
SGEN Seattle Genetics, Inc

-0.96 (-0.54%)

USD30.73B N/A N/A
MRNA Moderna, Inc

-0.95 (-1.38%)

USD27.16B N/A N/A
RPRX Royalty Pharma plc

+0.67 (+1.65%)

USD24.71B 33.37 9.15
GMAB Genmab A/S

+0.27 (+0.72%)

USD24.24B 25.60 2.90
BGNE BeiGene, Ltd

+7.49 (+2.94%)

USD23.25B N/A N/A
IMMU Immunomedics, Inc

-0.02 (-0.02%)

USD19.73B N/A N/A
INCY Incyte Corporation

+0.48 (+0.53%)

USD19.67B 47.64 35.20
BNTX BioNTech SE

+0.74 (+1.12%)

USD15.94B -99,999.99 N/A

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
BTEE:LSE iShares Nasdaq US Biotech.. 2.64 % 0.35 %

-0.06 (-0.98%)

USD0.24B
ZHU:CA BMO Equal Weight US Healt.. 2.08 % 0.35 %

N/A

USD0.03B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.06 (-0.91%)

USD0.07B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.03 (-0.62%)

USD0.24B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

-0.41 (-0.62%)

USD0.42B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.75%)

N/A
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

-0.53 (-0.39%)

USD9.52B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.33 (+1.07%)

USD0.01B
JKG iShares Morningstar Mid-C.. 0.00 % 0.25 %

-1.05 (-0.51%)

USD0.62B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

+0.03 (+0.05%)

USD0.08B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.72 (-1.01%)

USD0.21B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.53% 54% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.53% 53% F 65% D
Trailing 12 Months  
Capital Gain 10.83% 49% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.83% 49% F 65% D
Trailing 5 Years  
Capital Gain -31.49% 53% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.49% 52% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain -7.39% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.39% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.94% N/A N/A N/A N/A
Risk Adjusted Return -53.03% N/A N/A N/A N/A
Market Capitalization 25.55B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.27 29% F 34% F
Price/Book Ratio 2.21 74% C 50% F
Price / Cash Flow Ratio 12.25 7% F 25% F
EV/EBITDA 25.54 17% F 28% F
Management Effectiveness  
Return on Equity 8.19% 96% A 72% C-
Return on Invested Capital 17.95% 93% A 90% A-
Return on Assets 10.27% 97% A+ 96% A
Debt to Equity Ratio 21.07% 52% F 63% D
Technical Ratios  
Short Ratio 3.00 59% F 52% F
Short Percent 2.30% 77% C+ 59% F
Beta 1.40 56% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.